CDNA
$17.60
CareDx, Inc.
Recent News
How The CareDx (CDNA) Story Is Shifting With CMS LCD Uncertainty And New Guidance
CareDx’s fair value estimate has been reset from US$23.00 to US$24.80, a modest adjustment that reflects updated assumptions in the latest analyst models. This tweak comes as Wall Street remains split, with some analysts pointing to execution and valuation support, while others focus on reimbursement risk and longer term growth questions tied to the final CMS LCD. As you read on, you will see how these moving pieces shape the evolving CareDx narrative and what to watch next in the story. Stay...
CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference
CareDx (NASDAQ:CDNA) executives outlined the company’s transplant-focused strategy, recent financial performance, and 2026 priorities during remarks at the Raymond James Institutional Investor Conference. Chief Operating Officer and recently appointed Chief Financial Officer Keith Kennedy and Chief
CareDx, Inc Q4 2025 Earnings Call Summary
Moby summary of CareDx, Inc's Q4 2025 earnings call
CareDx Inc (CDNA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
CareDx Inc (CDNA) reports a 25% revenue increase in Q4 2025, while navigating potential impacts from regulatory changes and strategic investments.
CareDx Q4 Earnings Call Highlights
CareDx (NASDAQ:CDNA) reported fourth-quarter and full-year 2025 results alongside a detailed outlook for 2026, highlighting growth across its testing services, patient and digital solutions, and lab products businesses. Management also discussed continued improvements in revenue cycle management, pr